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Abstract
Background—The goal of vocal fold wound healing is the reconstitution of functional tissue, 
including a structurally and functionally intact epithelium. Mechanisms underlying 
reepithelialization in vocal folds are not known, although it is suspected that healing involves the 
interplay between several growth factors. We used a three-dimensional human embryonic stem 
cell-derived model of vocal fold mucosa to examine the effects of one growth factor, exogenous 
epidermal growth factor (EGF), on wound healing.
Materials and methods—A scratch wound was created in the in vitro model. Rate of wound 
healing, epidermal growth factor receptor (EGFR) activation, and cell proliferation post-injury 
were analyzed with and without application of both exogenous EGF and an EGFR inhibitor, 
Gefitinib.
Results—Wound repair after injury was significantly hastened by application of exogenous EGF 
(13.3 µm/hour, ±2.63) compared to absence of exogenous EGF (7.1 µm/hour ±2.84), but inhibited 
with concurrent addition of Gefitinib (5.2 µm/hour, ±2.23), indicating that EGF mediates wound 
healing in an EGFR-dependent manner. Immunohistochemistry revealed that EGFR activation 
occurred only in the presence of exogenous EGF. While not statistically significant, increased 
density of Ki67 staining in epithelium adjacent to the scratch wound was observed following 
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treatment with EGF, suggesting a tendency for exogenous EGF to increase epithelial cell 
proliferation.
Conclusions—Exogenous EGF increases the rate of wound healing in an EGFR-dependent 
manner in a three-dimensional stem cell-derived model of vocal fold mucosa. This model of 
wound healing can be used to gain insight into the mechanisms that regulate vocal fold epithelial 
repair following injury.
Keywords
vocal fold; epithelium; wound healing; scratch assay; epidermal growth factor; epidermal growth 
factor receptor
Introduction
Vocal folds are vulnerable to injury from trauma, penetrating neck wounds, surgical 
intubation, laryngeal infections and inflammation, and other mechanical, biological and 
chemical challenges. Aberrant healing from injury, or scarring, can result in the loss of the 
vibratory function of the vocal folds, negatively affecting quality and efficiency of voice 
production. The personal and public health impact of voice disorders is significant; voice 
disorders, in general, are associated with psychosocial costs for the individual [1], as well as 
short-term disability costs and work productivity losses comparable to asthma, heart disease 
and depression [2]. Meanwhile, effective techniques to prevent and remediate voice 
disorders, including those resulting from injury, are limited. Importantly, our ability to 
develop treatments to maximize healthy wound healing in human vocal folds in vivo is 
significantly compromised by the physical inaccessibility and ethical constraints associated 
with studying human vocal folds. Furthermore, the lack of human vocal fold epithelial cells 
from primary sources, their reduced proliferative capability and the absence of vocal fold 
epithelial cell lines have created few opportunities to study the pathophysiology of vocal 
fold wound healing in vitro. In the present study, for the first time, we used a novel three-
dimensional model of vocal fold mucosa to study wound healing in cells of human origin. 
Here, we examined the role for a potential treatment, exogenous epidermal growth factor 
(EGF), in hastening vocal fold epithelial wound healing. Further, we explored the role for 
the epidermal growth factor receptor (EGFR), in mediating EGF-dependent effects on 
wound healing.
Following injury to the vocal fold epithelium, a continuous, functionally intact epithelium 
must be restored. Regeneration of a complete epithelium occurs rapidly following resection 
of the vocal fold mucosa in animal models; within 3 days, a multilayered epithelium is 
restored in a rat model [3]. However, it takes up to five weeks for restoration of epithelial 
barrier function [4]. The cellular mechanisms underlying epithelial structural and functional 
regeneration are largely unknown. Likely, epithelial proliferation and migration following 
injury is guided by autocrine and paracrine signaling through growth factors, chemokines 
and cytokines by epithelial cells and fibroblasts, the most abundant cell type in vocal fold 
lamina propria. Recent work suggests that epithelial cells secrete growth factors that are 
important for wound healing. For example, epithelial cells secrete transforming growth 
factor beta 1 (TGF- β1) and TGF beta 3 following injury in an animal model (TGF-β3) [5]. 
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We have reported previously that EGF is secreted by epithelial cells in vitro in the absence 
of injury, and in vivo after injury [6]. EGF has been shown in a variety of tissues to promote 
epithelial proliferation and migration and research has indicated that EGF increases 
epithelial wound closure and shortens healing time [7,8]. Further, the epidermal growth 
factor receptor (EGFR), a receptor for ligands including EGF, is activated following vocal 
fold injury [6]. It has been proposed that EGFR, a member of the family of tyrosine kinase 
receptors, increases wound healing via second-messenger signaling [9]. Specifically, EGF-
EGFR interactions promote receptor dimerization, activation of the receptor kinase domain, 
and downstream phosphorylation of signaling molecules that promote cell proliferation and 
migration [10,11].
An in vitro model of vocal fold mucosa offers the opportunity to explore epithelial cell 
signaling during wound healing in a controlled, simplified environment. We previously 
created and characterized a human embryonic stem cell model of vocal fold mucosa [17]. 
The model mimics key morphologic and phenotypic features of an in vivo mucosa; it 
contains a multilayered epithelium and a basement membrane overlying a collagen gel 
containing fibroblasts. Epithelial cells showed presence of stratified, squamous cell markers 
(keratin 13 and keratin 14), as well as intercellular junctions (tight junctions, adherens 
junctions, gap junctions and desmosomes). In the present study, we exploited the model to 
examine epithelial regeneration following a scratch injury. Our aim was to explore how 
epidermal growth factor (EGF) and its receptor, the epidermal growth factor receptor 
(EGFR), mediate reepithelialization by cell proliferation in an in vitro model. We sought to 
determine if application of exogenous EGF after scrape injury increased wound healing in 
stem cell-derived epithelial cells of our three-dimensional model of vocal fold mucosa. 
Moreover, we sought to establish if reepithelialization following a scrape injury depended 
on EGFR activation in stem cell-derived epithelial cells. We hypothesized that exogenous 
EGF would increase EGFR activation and cell proliferation resulting in more rapid wound 
closure. In addition, we hypothesized that wound healing would be slowed or incomplete in 
the absence of EGFR activation.
Methods
Derivation of simple epithelial cells and creation of 3D tissue construct
Nine three-dimensional stem cell-derived constructs of vocal fold mucosa were created as 
described previously [17]. Briefly, simple epithelial cells were differentiated from a human 
embryonic stem cell line (WA09) via retinoic acid treatment [18,19]. The resulting keratin 
18 (K18) and p63-expressing cells were placed on a collagen I gel seeded with vocal fold 
fibroblasts that were characterized elsewhere (T21 cell line) [20]. The gels were submerged 
with flavinoid adenine dinucleotide (FAD) medium and placed in a 37°C incubator. The 
medium contained Ham’s F-12/DMEM (3:1 ratio), FBS (2.5%), hydrocortisone (0.4µg/ml), 
cholera toxin (8.4 ng/ml), insulin (5 µg/ml), adenine (24 µg/ml), epidermal growth factor (10 
ng/ml), penicillin (100 U/ml) and streptomycin (0.01 mg/ml). After two days, medium was 
removed from the gel surface to create an air liquid interface (ALI). Medium was refreshed 
every two days.
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Following 19–21 days at the ALI, three 3D constructs were submerged overnight in a low-
serum medium (DMEM with 0.5% FBS). A scratch-wound of approximately 0.5 mm in 
thickness was created along the engineered epithelium to the depth of the collagen substrate 
using a 100 µl sterile pipette. The constructs were gently rinsed with low-serum medium to 
remove debris and assigned to one of three experimental conditions. Under the control 
condition the scratched gels were immersed in low-serum medium only. Under the EGF 
condition, scratched gels were immersed in medium supplemented with exogenous 
epidermal growth factor (100 ng). Under the EGF, Gefitinib condition, gels were pretreated 
for one hour before injury with Gefitinib (1 µM) [21], an epidermal growth factor (EGFR) 
inhibitor. Subsequently, these gels were submerged in medium containing EGF and 
Gefitinib (1 µM) after injury. Experiments were completed in triplicate.
Wound Closure
Gels were imaged immediately and 24 hours after injury using an Olympus CKX41 
microscope and Spot software (Version 4.6; Diagnostic Instruments). Wound width 
(microns) and rate of healing (microns per hour) were measured by three raters using ImageJ 
[22]. At 24 hours, gels were fixed in formalin and processed for routine 
immunohistochemistry.
Immunohistochemistry
Cultures were fixed in 4% paraformaldehyde, processed, and embedded in paraffin. 
Standard hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) analyses 
were performed. For IHC, antigen retrieval was achieved using heat-activated 10 mM 
sodium citrate buffer (pH 6). Sections were incubated overnight at 4°C using antibodies 
directed against the proliferation marker, Ki67 (1:100; ab16667, Abcam, Cambridge, MA) 
and a marker of phosphorylated epidermal growth factor receptor, an anti-tyrosine 1068 
antibody (Tyr1068, 1:100; #3777, Cell Signaling Technology, Danvers, MA). A Ki67 
labeling index was used to measure rate of proliferation of epithelial cells. The index was 
calculated by dividing the number of Ki67-positive epithelial cells by the total number of 
epithelial cells within a ten - cell width of either side of the wound.
Statistical analyses
Three raters measured wound width, Ki67 labeling, and identified presence or absence of 
EGFR staining. Statistical significance between treatment means for rate of healing (µm/hr) 
and Ki67 labeling was determined through use of a one- way analysis of variance 
(ANOVA). In addition, intraclass and interclass coefficients were included in the data 
analysis of rate of healing and Ki67 labeling to assess intra and inter rater reliability. Percent 
agreement in terms of identification of staining was used to determine intra- and inter-rater 
reliability for EGFR data. Inter-rater reliability for 100% of images was obtained for rate of 
judgments of wound healing and Ki67 labeling. Intra-rater reliability was completed on 20% 
of the sections selected at random. Data for each treatment variable were obtained as 
follows:
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Wound width—Change in wound width over time, rate of healing, for each treatment was 
determined by visually identifying the area of most closure in each wound at 24 hours post-
injury. The original wound width of that area was measured, as well as the wound width at 
24 hours post-injury. Rate of healing in µm/hr was then determined.
Proliferation rate—Ki67 labeling index was determined by finding the wound edge and 
counting 10 cells along the basal layer in the direction away from the injury. This was 
repeated for both sides of the wound. The cell area contained within that 10-cell width was 
assessed for ki67 labeling. The percentage of cells labeled for Ki67 was determined for each 
side of the wound and an average of the two wound edges was calculated.
EGFR staining—Determination of the presence of staining for activated EGFR was 
conducted in a binary manner. Raters answered either “yes” or “no” to the presence of 
staining around the wound edge.
Results
We examined the roles of exogenous EGF and its receptor, EGFR, in a stem cell-derived 
model of vocal fold epithelium following injury. Scratch wounds were created in mucosa 
(Figure 1). Epithelial regeneration was observed following scratch wound injury in the 
presence and absence of exogenous EGF (Table 1). However, the rate of healing was 
significantly faster following addition of EGF compared to absence of EGF or concurrent 
treatment with EGF and an EGFR inhibitor, Gefitinib (ANOVA, p=0.019). Intra-rater and 
inter-rater correlation coefficients were 0.92 and 0.88, respectively.
Cell proliferation was observed in all epithelium following scratch injury (Figure 2). At 24 
hours post injury, an increased density and heterogeneous distribution of Ki67, or number 
(%) of positive cells across all epithelial layers, was observed in the epithelium surrounding 
the scratch wound area under all conditions (Figure 3; Table 2). However, Ki67 labeling 
index was greatest in the EGF-treated samples (ANOVA, p=0.16). Intra-rater and inter-rater 
reliability for measurement of the Ki67 index were high, at 0.96 and 0.95, respectively.
Activated EGFR was observed only following EGF treatment at 24 hours post-injury 
(Figure 3). EGFR activation was found in all layers of the epithelium under that condition. 
EGFR activation was not observed when EGF was omitted from the medium or when both 
EGF and the EGFR inhibitor, Gefitinib, were present. Inter-rater and intra-rater reliability 
were 0.89 and 0.89, respectively.
Discussion
Vocal fold mucosa is composed of a stratified, squamous epithelium and a lamina propria 
containing multiple cell types, including fibroblasts. Vocal fold wound healing likely 
involves complex interactions between the various cell types, as well as between cells and 
the extracellular matrix. As a step towards elucidating the cellular mechanisms underlying 
epithelial repair after vocal fold injury, we examined the role of a growth factor, EGF, and 
its receptor, EGFR, in reepithelialization in a human embryonic stem cell-derived three-
dimensional in vitro model of vocal fold injury. We observed that exogenous EGF hastened 
Palencia et al. Page 5













the rate of wound healing at 24 hours post-scratch injury. This effect was not observed 
following inhibition of the EGFR, indicating that EGF mediated its effects in an EGFR-
dependent manner.
Elucidating mechanisms underlying early epithelial regeneration is an important prerequisite 
for understanding the role of epithelial cells in normal and aberrant healing, as well as 
identifying treatment to induce rapid and complete healing. Following vocal fold injury, the 
fundamental goal of wound healing is the reconstitution of functional mucosa, including the 
epithelium. Restoration of a continuous, multilayered epithelium occurs within days 
following wound healing, while return of a functional barrier takes up to five weeks post-
injury [4]. The lag in restoration of barrier function theoretically renders the epithelium 
vulnerable to damage from chemical, biological and mechanical insults during this time. 
Consequently, efforts towards elucidating and manipulating healing at a cellular level have 
high therapeutic relevance.
Exogenous growth factors have been shown to reduce scarring in lamina propria in animal 
models following injury [13–16]. Exogenous application of TGF-β3 suppresses vocal fold 
scar formation in dog [2] and rat [5] models. Similarly, exogenous hepatocyte growth factor 
(HGF) [13], 5-amino acid deleted type HGF (dHGF) [14], and basic fibroblast growth factor 
(bFGF) [15,16] improve outcomes post-injury in animal models. Consequently, application 
of growth factors offers a promising approach to enhancing the rate and completeness of 
wound healing. To understand the mechanisms by which growth factors suppress scarring, 
several studies examined the effects of exogenous growth factors at the cellular level, 
specifically using cultured vocal fold fibroblasts. Exogenous HGF, EGF, bFGF and TGF-β1 
increased hyaluronan synthesis by fibroblasts [23]. Elsewhere, exogenous HGF upregulated 
production of endogenous HGF, TGF- β1, as well as other growth factors in rat fibroblasts 
[24]. In the single paper that explored the effects of EGF on vocal fold fibroblast behavior in 
a scratch assay, no appreciable increase in fibroblast migration was reported [25]. Likely, 
the effects of EGF on vocal fold fibroblast proliferation and migration are cell, dose and 
substrate specific [26]. To the best of our knowledge, there are no reports on the effects of 
growth factors on vocal fold epithelial cells. This work suggests that epithelial cells provide 
a responsive target for treatment with growth factors.
We acknowledge several limitations to this study. First, EGFR serves as a receptor for 
various growth factors, only one of which, EGF, was studied in the present work. 
Consequently, the present study does not attempt to capture the complexity of inhibitory and 
excitatory effects induced by competing ligand growth factors such as HGF which is 
expressed in vocal folds following injury [27]. Second, vocal fold response to injury likely 
involves complex, undefined epithelial-mesenchymal interactions. By focusing on 
epithelium, we gleaned important, yet incomplete insight into the effects of exogenous EGF 
on cell proliferation and rate of wound healing. EGF may alter behavior of other cells, 
including fibroblasts [23,25], which play a critical role in determining the biomechanical 
properties of lamina propria post-injury through their impact on the composition of the 
extracellular matrix. Future study of the effects of exogenous EGF on fibroblasts and 
epithelial-fibroblast interactions using our model could provide important insights into 
lamina propria remodeling, a common and undesirable effect of injury. Third, epithelial 
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healing begins immediately after wound healing and continues until a complete epithelium 
has been restored. Here we examined the early phase of wound healing. We selected 24 
hours as an end point for this study; while additional time points may have provided insight 
into the speed of EGFR-activation on wound healing, epithelial proliferation has been shown 
to peak in an animal model at one day post injury {28]. Finally, scratch injury to our in vitro 
model has not been characterized previously, consequently, the ability of the model to 
mimic the in vivo response to injury is unknown. However, our observations of EGFR 
activation and cell proliferation in response to injury in the present study are consistent with 
those reported elsewhere in an in vivo model of injury [6]. These findings lend support the 
use of the in vitro model to explore vocal fold wound healing in a controlled environment.
Notwithstanding the above limitations, this study has provided us with important and 
clinically relevant insights into EGF-mediated vocal fold healing. Specifically, our study 
shows that EGF hastens wound healing in an EGFR-dependent manner. Further, we 
validated that the stem cell-derived 3D model of vocal fold mucsoa can be used to explore 
mechanisms that enable and regulate epithelial repair following mechanical injury. This 
work provides necessary groundwork for developing treatments that hasten 
reepithelialization and, consequently, improve host tissue protection following mechanical 
injury.
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Figure 1. Epithelial wound 24 hours after scratch injury
Hematoxylin and eosin (H&E) staining showing epithelium (E), collagen gel seeded with 
fibroblast (blue) to mimic lamina propria (LP) in an uninjured model of vocal fold mucosa 
(A). The mucosa is shown 24 hours after scratch injury under in the presence of the growth 
factor, EGF, only (B), absence of EGF (C), and EGF with the EGFR inhibitor Gefitinib (D). 
A dashed line indicates scratch injury. Experiments were completed in triplicate. Images of 
representative scratch wounds are shown here. Scale bar: 500 µm.
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Figure 2. EGFR activation and epithelial cell proliferation 24 hours after scratch injury
Presence of brown staining (arrow) indicates EGFR activation in epithelial cells adjacent to 
the scratch in a multilayered stem cell derived epithelium following treatment with EGF (A). 
No EGFR activation was observed following treatment with EGF and the EGFR inhibitor, 
Gefitinib (B), in the absence of exogenous EGF treatment (C), and in uninjured mucosa (D). 
A dashed line indicates scratch injury. Experiments were completed in triplicate. Images of 
representative scratch wounds are shown here. Scale bar: 500 µm.
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Figure 3. Epithelial cell proliferation 24 hours after scratch injury
Immunohistochemistry for the cell proliferation marker Ki67 shows prolific brown staining 
(arrow) in epithelial cells under the EGF only condition. Staining was observed, albeit at 
lower levels, in the absence of EGF (B) and following simultaneous treatment of EGF and 
Gefitinib (C). Staining was absent in uninjured mucosa (D). A dashed line indicates scratch 
injury. Experiments were completed in triplicate. Images of representative scratch wounds 
are shown here. Scale bar: 500 µm.
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Table 1
Healing rate under three experimental conditions
Treatment condition Mean rate of healing
in microns/hr (± 1 SD)
EGF, No Gefitinib 13.3 (±2.63)
EGF, Gefitinib 5.2 (±2.23)
No EGF, No Gefitinib 7.1 (±2.84)
The mean rate of healing was significantly higher under the EGF condition at 24 hours post-scratch assay (p=0.019) compared to absence of EGF 
or presence of both EGF and the EGFR inhibitor, Gefitinib. Standard deviations are shown in parentheses. Experiments were conducted in 
triplicate.
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Table 2
Ki67 labeling index under three experimental conditions
Treatment condition Mean Ki67 labeling index
(± 1 SD)
EGF, No Gefitinib 0.363 (±.05)
EGF, Gefitinib 0.125 (±.20)
No EGF, No Gefitinib 0.210 (±.10)
The mean rate of healing showed a higher, while not significantly significant (p=0.16), Ki67 labeling index in the presence of EGF at 24 hours 
post-injury compared to absence of EGF or presence of both EGF and the EGFR inhibitor, Gefitinib. Standard deviations are shown in parentheses. 
Experiments were conducted in triplicate.
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